NVAX Novavax Stock Analysis: 5 Risks After Aug 27 FDA Approval - Thursday Predicted Opening Price?📈

1. What are the key risks for Novavax (NVAX) stock after FDA approval?

After the FDA approval on August 27, Novavax faces risks such as competition from other COVID-19 vaccine manufacturers, potential supply chain disruptions, regulatory hurdles in other countries, fluctuating demand for vaccines, and possible dilution from future capital raises.

2. What is the predicted opening price for NVAX stock on Thursday?

While exact predictions are speculative, analysts suggest that NVAX stock could open higher on Thursday if market sentiment remains bullish post-FDA approval. However, volatility is expected due to profit-taking and broader market conditions.

3. How does Bitcoin and altcoin performance in October relate to NVAX stock?

Bitcoin and altcoin trends are unrelated to NVAX stock performance. The mention of 'making millions with altcoins in October' is likely part of a separate discussion on cryptocurrency opportunities and should not be conflated with biotech stock analysis.